Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

StockNews.com upgraded shares of Eli Lilly and Company (NYSE:LLY – Free Report) from a hold rating to a buy rating in a research report report published on Wednesday morning. A number of other ...

Data shows that Lilly’s Zepbound has about 40% share in the US ... Many smaller companies are developing similar products, ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.